What is the role of nucleoside analogues and combinations in the treatment of mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


A higher complete response rate and/or longer response duration has been suggested when fludarabine is used in combination with an alkylator (eg, FC), with an anthracycline (eg, FND or fludarabine plus idarubicin), or both (eg, FCM). Such combinations could be used in refractory or relapse settings, with comparable response rates and duration of response.

The addition of rituximab to all of these regimens is clearly beneficial. For example, with FCM in a series of 38 patients with relapsed MCL, the overall response rate was 65% with rituximab versus 33% without rituximab, and the complete response rate was 35% with rituximab versus 0% without rituximab. [17]

Other nucleoside analogs have activity in MCL. For example, cladribine was found to be superior in combination with mitoxantrone.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!